CN113804890A - 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用 - Google Patents
尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用 Download PDFInfo
- Publication number
- CN113804890A CN113804890A CN202010543777.8A CN202010543777A CN113804890A CN 113804890 A CN113804890 A CN 113804890A CN 202010543777 A CN202010543777 A CN 202010543777A CN 113804890 A CN113804890 A CN 113804890A
- Authority
- CN
- China
- Prior art keywords
- burn
- cell death
- programmed cell
- urine
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 31
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 31
- 239000012634 fragment Substances 0.000 title claims abstract description 23
- 101000734646 Homo sapiens Programmed cell death protein 6 Proteins 0.000 title claims abstract description 19
- 102100034785 Programmed cell death protein 6 Human genes 0.000 title claims abstract description 19
- 230000003993 interaction Effects 0.000 title claims abstract description 19
- 101710198445 Programmed cell death 6-interacting protein Proteins 0.000 claims abstract description 13
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 claims abstract description 13
- 238000011156 evaluation Methods 0.000 claims abstract description 12
- 238000003745 diagnosis Methods 0.000 claims abstract description 10
- 238000012544 monitoring process Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000011160 research Methods 0.000 claims abstract description 7
- 238000004393 prognosis Methods 0.000 claims abstract description 5
- 238000003748 differential diagnosis Methods 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims abstract description 4
- 230000007246 mechanism Effects 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims description 15
- 238000003908 quality control method Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000007790 solid phase Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000013558 reference substance Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 239000012089 stop solution Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 238000004321 preservation Methods 0.000 abstract description 2
- 238000005070 sampling Methods 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000004796 pathophysiological change Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- PIXQDIGKDNNOOV-GUBZILKMSA-N Ala-Lys-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O PIXQDIGKDNNOOV-GUBZILKMSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- NECWUSYTYSIFNC-DLOVCJGASA-N Asp-Ala-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NECWUSYTYSIFNC-DLOVCJGASA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NNQHEEQNPQYPGL-FXQIFTODSA-N Gln-Ala-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NNQHEEQNPQYPGL-FXQIFTODSA-N 0.000 description 1
- JRHPEMVLTRADLJ-AVGNSLFASA-N Gln-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JRHPEMVLTRADLJ-AVGNSLFASA-N 0.000 description 1
- VCUNGPMMPNJSGS-JYJNAYRXSA-N Gln-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VCUNGPMMPNJSGS-JYJNAYRXSA-N 0.000 description 1
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- BQYZXYCEKYJKAM-VGDYDELISA-N His-Cys-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQYZXYCEKYJKAM-VGDYDELISA-N 0.000 description 1
- PBVQWNDMFFCPIZ-ULQDDVLXSA-N His-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 PBVQWNDMFFCPIZ-ULQDDVLXSA-N 0.000 description 1
- JXUGDUWBMKIJDC-NAKRPEOUSA-N Ile-Ala-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JXUGDUWBMKIJDC-NAKRPEOUSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- RSFGIMMPWAXNML-MNXVOIDGSA-N Leu-Gln-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RSFGIMMPWAXNML-MNXVOIDGSA-N 0.000 description 1
- GUYHHBZCBQZLFW-GUBZILKMSA-N Lys-Gln-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N GUYHHBZCBQZLFW-GUBZILKMSA-N 0.000 description 1
- ULUQBUKAPDUKOC-GVXVVHGQSA-N Lys-Glu-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ULUQBUKAPDUKOC-GVXVVHGQSA-N 0.000 description 1
- YLLWCSDBVGZLOW-CIUDSAMLSA-N Met-Gln-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O YLLWCSDBVGZLOW-CIUDSAMLSA-N 0.000 description 1
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- LRBSWBVUCLLRLU-BZSNNMDCSA-N Phe-Leu-Lys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O LRBSWBVUCLLRLU-BZSNNMDCSA-N 0.000 description 1
- ZLAKUZDMKVKFAI-JYJNAYRXSA-N Phe-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O ZLAKUZDMKVKFAI-JYJNAYRXSA-N 0.000 description 1
- 102000002020 Protease-activated receptors Human genes 0.000 description 1
- 108050009310 Protease-activated receptors Proteins 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 1
- YYZPVPJCOGGQPC-JYJNAYRXSA-N Tyr-His-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYZPVPJCOGGQPC-JYJNAYRXSA-N 0.000 description 1
- OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供一种尿液程序性细胞死亡6相互作用蛋白(Programmed cell death 6‑interacting protein)及其多肽片段的应用,具体为尿液程序性细胞死亡6相互作用蛋白及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。烧伤是日常生活中常见的重要创伤,每年每100万人中约有5 000~100000人烧伤,据世界卫生组织统计,每年全球死于烧伤患者超过30万人,严重烧伤救治存活率仍处于较低水平。本发明通过研究证实,与健康人(正常对照组)相比,尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤患者中表达下调。可用于烧伤患者的辅助诊断及病情监测。本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势,利用尿液标本检测尿液程序性细胞死亡6相互作用蛋白及其多肽片段。
Description
技术领域
本发明涉及尿液程序性细胞死亡6相互作用蛋白及其多肽片段的新用途,具体涉及尿液程序性细胞死亡6相互作用蛋白及其多肽片段在于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等的应用。
背景技术
烧伤是指由于火焰、高温气体、灼热的固体或液体、放射线、电能、强酸强碱等化学物质所引起的人体皮肤、组织甚至深层脏器的损伤,是一种全身性综合性疾病。烧伤后创面组织大量坏死、感染、休克及凝血功能障碍等反应可引起机体发生一系列的病理生理学变化。不同程度的烧伤对人体有着不同的影响,严重的烧伤可对人体内环境造成破坏,使烧伤患者出现各系统复杂性的病理生理变化,相关的检测指标也会随着烧伤严重程度的不同随之出现相应的改变。及时检测这些指标的变化可为临床医生对于疾病的诊断,病情的判断,治疗方法的选择以及患者预后的评估等多方面提供有价值的参考依据。
但是,严重烧伤的病人皮肤完整性较差,血液学检测作为皮肤有创性检查在此类患者的临床应用中存在着诸多困难,反复的抽血检测还会加剧患者痛苦。尿液作为血液的超滤液蕴含着丰富的生物学信息,其采集过程具有无创便捷等优势,这在烧伤患者的检测中尤为明显。在尿液中寻找有助于烧伤诊断及反映病情变化的生物标志物,可提高烧伤患者的生活质量和依从性,减轻多次采血的痛苦,更好的为临床医生提供有利于疾病诊断和治疗的参考依据。
程序性细胞死亡6相互作用蛋白 (Programmed cell death 6-interactingprotein, PDCD6IP)在机体内具有多种生物学功能,例如与钙依赖性蛋白的结合、蛋白酶激活受体结合及蛋白质同源二聚化的活化。其还在多种生物学过程中起重要作用,例如凋亡过程、肌球蛋白收缩环的装配以及维持上皮细胞极性等。本研究烧伤患者尿液中程序性细胞死亡6相互作用蛋白较健康人组出现表达下调,烧伤患者尿液中该蛋白含量降低。
与常用的临床血液样本相比,尿液可以完全无创、连续、大量收集;没有稳态调节,可累积更多种类、更大幅度的变化,机体的很多病理生理变化可能体现在尿液中。一些激素和细胞因子等分子量相对较小的蛋白多肽入血后,会很快被排泄进入尿液,这些蛋白和多肽在尿液中被检测到的概率比在血中大很多;尿液收集之前,尿中可能的蛋白降解过程已经完成,所以尿蛋白可在较长时间内保持稳定。为减轻烧伤患者多次采血的痛苦,本实验在前期方法学摸索的基础上,期望通过尿液蛋白或多肽研究,实现用无痛、方便、快捷、易重复的尿液检测辅助烧伤患者的诊断及病情监测,也为进一步尿液多肽检测试剂盒的研究奠定基础。
发明内容
本发明的目的在于提供一种尿液程序性细胞死亡6相互作用蛋白及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。
优选地,所述尿液程序性细胞死亡6相互作用蛋白的氨基酸序列如SEQ ID NO.1所示(MLAQAQEVFF LKATRDKMKD AIIAKLANQA ADYFGDAFKQ CQYKDTLPKE VFPVLAAKHCIMQANAEYHQ SILAKQQKKF GEEIARLQIH PFTES);或由SEQ ID NO.1所示的氨基酸序列衍生的,且与SEQ ID NO.1所示的氨基酸序列具有相同功能的氨基酸序列。
优选地,所述制剂为烧伤患者尿液程序性细胞死亡6相互作用蛋白及其多肽片段检测试剂盒。
优选地,所述试剂盒包括抗原抗体反应的免疫方法及其试剂盒如能够特异性结合程序性细胞死亡6相互作用蛋白及其多肽片段的适配体抗体或抗体片段中的一种或多种。
优选地,所述检测方法包括直接检测程序性细胞死亡6相互作用蛋白及其多肽片段的质谱等方法及其相关试剂盒。
优选地,所述检测方法包括直接检测程序性细胞死亡6相互作用蛋白及其多肽片段的相关核酸检测等方法及其相关试剂盒。
优选地,所述试剂盒还包括选自下组的成分:固相载体,稀释液,对照品,标准品,质控品,检测抗体,第二抗体、第二抗体稀释液,发光试剂,洗涤液、显色液、终止液中的任意一种或几种的组合。
优选地,所述标准品包括程序性细胞死亡6相互作用蛋白标准品、人源化标签抗体标准品;较佳地,所述质控品包括:程序性细胞死亡6相互作用蛋白质控品、人源化标签抗体质控品;较佳地,所述固相载体包括:微粒、微球、玻片、试纸条、塑料珠、液相芯片、微孔板或亲和膜等以及同等功能的其他载体。
优选地,所述固相载体的材质为聚氯乙烯、聚苯乙烯、聚丙酰胺、纤维素中的任意一种及具有类似功能的载体。
发明人首先收集了健康人、烧伤患者的尿液标本, 4000r/min离心5min后,吸取上清,采用Bradford法测定提取的蛋白浓度,进行SDS-PAGE酶解。尿液样本的Label-free质谱分析由OrbitrapFusion型质谱完成。将烧伤组和正常对照组在质谱中得到的数据采用Maxquant算法中的Labelfree算法进行非标记定量计算。以蛋白表达量差异在1.5倍以上且经统计检验P<0.05作为参考标准筛选差异性多肽。然后发明人对具有统计学意义的差异性多肽进行鉴定,利用数据库检索得到差异蛋白程序性细胞死亡6相互作用蛋白。
本发明通过研究证实与健康人相比,程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤患者的尿液中呈低表达,与临床诊断有较好的一致性。从而提出检测尿液程序性细胞死亡6相互作用蛋白及其多肽片段可用于烧伤的辅助诊断或病情监测。
本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势,利用尿液标本检测尿液程序性细胞死亡6相互作用蛋白及其多肽片段。
为让本发明的上述和其它目的、特征和优点能更明显易懂,下文特举较佳实施例,并配合附图,作详细说明如下。
附图说明
图1是尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤组及健康对照组中含量图。
图2是程序性细胞死亡6相互作用蛋白参与主要生物过程示意图。
具体实施方式
实施例1 尿液标本的收集与处理
选取烧伤患者作为烧伤组,选取同期健康体检者作为正常对照组。收集各组研究对象入院后的新鲜晨尿样本30ml,不能正常排尿者收集其早晨导尿管中尿液,置于干燥、洁净的容器内。将收集的尿液标本4000r/min离心5min后,吸取上清,每管2ml分装,-80℃冰箱保存。
实施例2 质谱分析和尿液多肽的筛选
对尿液样品蛋白提取,并对提取的蛋白浓度进行测定。尿液样本的质谱分析由OrbitrapFusion型质谱完成。将实验组和正常对照组在质谱中得到的数据进行定量计算。组间比较采用t-test进行差异分析,以蛋白表达量差异在1.5倍以上且经统计检验P<0.05作为参考标准筛选差异表达蛋白。
实施例3 差异多肽的鉴定及分析
本次使用的数据库为Uniprot_Homo数据库,产生的质谱原始文件采用MaxQuant软件处理,检索参数设置见表1。
与健康人相比,程序性细胞死亡6相互作用蛋白在烧伤患者的尿液中低表达,如图1所示,其参与的主要生物过程如图2所示,程序性细胞死亡6相互作用蛋白在正常对照组和烧伤组尿液中的表达有显著性差异。
虽然本发明已以较佳实施例披露如上,然其并非用以限定本发明,任何所属技术领域的技术人员,在不脱离本发明的精神和范围内,当可作些许的更动与改进,因此本发明的保护范围当视权利要求所界定者为准。
SEQUENCE LISTING
<110> 首都医科大学附属北京世纪坛医院
<120> 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用
<130> 1
<140> 20PPDCD6IP
<141> 2020-05-10
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 95
<212> PRT
<213> Human Urine
<400> 1
Met Leu Ala Gln Ala Gln Glu Val Phe Phe Leu Lys Ala Thr Arg Asp
1 5 10 15
Lys Met Lys Asp Ala Ile Ile Ala Lys Leu Ala Asn Gln Ala Ala Asp
20 25 30
Tyr Phe Gly Asp Ala Phe Lys Gln Cys Gln Tyr Lys Asp Thr Leu Pro
35 40 45
Lys Glu Val Phe Pro Val Leu Ala Ala Lys His Cys Ile Met Gln Ala
50 55 60
Asn Ala Glu Tyr His Gln Ser Ile Leu Ala Lys Gln Gln Lys Lys Phe
65 70 75 80
Gly Glu Glu Ile Ala Arg Leu Gln Ile His Pro Phe Thr Glu Ser
85 90 95
Claims (9)
1.尿液程序性细胞死亡6相互作用蛋白及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。
2.根据权利要求1所述的应用,其特征在于,所述尿液程序性细胞死亡6相互作用蛋白的氨基酸序列如SEQ ID NO.1所示;或由SEQ ID NO.1所示的氨基酸序列衍生的,且与SEQID NO.1所示的氨基酸序列具有相同功能的氨基酸序列。
3.根据权利要求1所述的应用,其特征在于,所述制剂为烧伤患者尿液程序性细胞死亡6相互作用蛋白及其多肽片段检测试剂盒。
4.根据权利要求3所述的应用,其特征在于,所述试剂盒包括抗原抗体反应的免疫方法及其试剂盒如能够特异性结合程序性细胞死亡6相互作用蛋白及其多肽片段的适配体抗体或抗体片段中的一种或多种。
5.根据权利要求3所述的应用,其特征在于,所述检测方法包括直接检测程序性细胞死亡6相互作用蛋白及其多肽片段的质谱等方法及其相关试剂盒。
6.根据权利要求3所述的应用,其特征在于,所述检测方法包括直接检测程序性细胞死亡6相互作用蛋白及其多肽片段或其相关核酸检测等方法及其相关试剂盒。
7.根据权利要求3所述的应用,其特征在于,所述试剂盒还包括选自下组的成分:固相载体,稀释液,对照品,标准品,质控品,检测抗体,第二抗体、第二抗体稀释液,发光试剂,洗涤液、显色液、终止液中的任意一种或几种的组合。
8.根据权利要求7所述的应用,其特征在于,所述标准品包括程序性细胞死亡6相互作用蛋白标准品、人源化标签抗体标准品;较佳地,所述质控品包括:程序性细胞死亡6相互作用蛋白控品、人源化标签抗体质控品;较佳地,所述固相载体包括:微粒、微球、玻片、试纸条、塑料珠、液相芯片、微孔板或亲和膜等以及同等功能的其他载体。
9.根据权利要求8所述的应用,其特征在于,所述固相载体的材质为聚氯乙烯、聚苯乙烯、聚丙酰胺、纤维素中的任意一种及具有类似功能的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010543777.8A CN113804890A (zh) | 2020-06-15 | 2020-06-15 | 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010543777.8A CN113804890A (zh) | 2020-06-15 | 2020-06-15 | 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113804890A true CN113804890A (zh) | 2021-12-17 |
Family
ID=78944143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010543777.8A Pending CN113804890A (zh) | 2020-06-15 | 2020-06-15 | 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113804890A (zh) |
-
2020
- 2020-06-15 CN CN202010543777.8A patent/CN113804890A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113777314A (zh) | 尿液踝蛋白1及其多肽片段在烧伤中的应用 | |
CN113804890A (zh) | 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用 | |
CN113804895A (zh) | 尿液免疫球蛋白重链可变区3-7及其多肽片段在烧伤中的应用 | |
CN113759122A (zh) | 尿液蛋白质z及其多肽片段在烧伤中的应用 | |
CN113804889A (zh) | 尿液XII型胶原蛋白α1链及其多肽片段在烧伤中的应用 | |
CN113804894A (zh) | 尿液肿瘤坏死因子受体超家族成员19l及其多肽片段在烧伤中的应用 | |
CN113777315A (zh) | 尿液泛素样蛋白isg15及其多肽片段在烧伤中的应用 | |
CN113777305A (zh) | 尿液单腺苷二磷酸核糖基化转移酶及其多肽片段在烧伤中的应用 | |
CN113777316A (zh) | 尿液C4b结合蛋白α链及其多肽片段在烧伤中的应用 | |
CN113759123A (zh) | 尿液软骨间层蛋白及其多肽片段在烧伤中的应用 | |
CN113777313A (zh) | 尿液维生素k依赖性蛋白s及其多肽片段在烧伤中的应用 | |
CN113759125A (zh) | 尿液子宫珠蛋白及其多肽片段在烧伤中的应用 | |
CN114113580A (zh) | 尿液血栓调节蛋白及其多肽片段在烧伤中的应用 | |
CN113804893A (zh) | 尿液I型胶原蛋白α1链及其多肽片段在烧伤中的应用 | |
CN113777304A (zh) | 尿液纤维蛋白溶解酶原及其多肽片段在烧伤中的应用 | |
CN113777306A (zh) | 尿液果糖二磷酸醛缩酶b及其多肽片段在烧伤中的应用 | |
CN113820485A (zh) | 尿液碳酸酐酶3及其多肽片段在烧伤中的应用 | |
CN114113600A (zh) | 尿液α1-抗胰蛋白酶及其多肽片段在烧伤中的应用 | |
CN113777303A (zh) | 尿液凝血酶原及其多肽片段在烧伤中的应用 | |
CN113777317A (zh) | 尿液主穹隆蛋白及其多肽片段在烧伤中的应用 | |
CN113759121A (zh) | 尿液免疫球蛋白κ可变区3D-7及其多肽片段在烧伤中的应用 | |
CN114113640A (zh) | 尿液凝血因子ix及其多肽片段在烧伤中的应用 | |
CN113777302A (zh) | 尿液补体因子d及其多肽片段在烧伤中的应用 | |
CN113804892A (zh) | 尿液脂肪酸结合蛋白4及其多肽片段在烧伤中的应用 | |
CN113804891A (zh) | 尿液c反应蛋白及其多肽片段在烧伤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |